These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3923750)

  • 1. Involvement of complement in atopic dermatitis.
    Kapp A; Schöpf E
    Acta Derm Venereol Suppl (Stockh); 1985; 114():152-4. PubMed ID: 3923750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of complement in psoriasis and atopic dermatitis--measurement of C3a and C5a, C3, C4 and C1 inactivator.
    Kapp A; Wokalek H; Schöpf E
    Arch Dermatol Res; 1985; 277(5):359-61. PubMed ID: 3875319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Atopic dermatitis. II. The status of complement proteins and the pathogenetic role of anaphylatoxins C4a, C3a and C5a].
    Sergeev IuV; Reznikov IuP; Lobanova EV; Pimenova NS
    Vestn Dermatol Venerol; 1989; (4):4-7. PubMed ID: 2788339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C3, C5 components and C3a, C4a, and C5a fragments of the complement system.
    Janatova J
    Methods Enzymol; 1988; 162():579-625. PubMed ID: 3265757
    [No Abstract]   [Full Text] [Related]  

  • 5. Anaphylatoxin generation in multisystem organ failure.
    Heideman M; Hugli TE
    J Trauma; 1984 Dec; 24(12):1038-43. PubMed ID: 6334754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement activation during storage of whole blood, red cells, plasma, and buffy coat.
    Hyllner M; Arnestad JP; Bengtson JP; Rydberg L; Bengtsson A
    Transfusion; 1997 Mar; 37(3):264-8. PubMed ID: 9122898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis.
    Hack CE; Nuijens JH; Felt-Bersma RJ; Schreuder WO; Eerenberg-Belmer AJ; Paardekooper J; Bronsveld W; Thijs LG
    Am J Med; 1989 Jan; 86(1):20-6. PubMed ID: 2783358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demonstration of anaphylatoxins C3a, C4a and C5a in the scales of psoriasis and inflammatory pustular dermatoses.
    Takematsu H; Ohkohchi K; Tagami H
    Br J Dermatol; 1986 Jan; 114(1):1-6. PubMed ID: 3484631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaphylatoxin levels in human aqueous humor.
    Mondino BJ; Sumner H
    Invest Ophthalmol Vis Sci; 1986 Aug; 27(8):1288-92. PubMed ID: 3488296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement profile in a C1 inhibitor deficient family.
    Sayama K; Shiraishi S; Miki Y
    Br J Dermatol; 1985 Dec; 113(6):737-43. PubMed ID: 4096884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease.
    Belmont HM; Hopkins P; Edelson HS; Kaplan HB; Ludewig R; Weissmann G; Abramson S
    Arthritis Rheum; 1986 Sep; 29(9):1085-9. PubMed ID: 3489467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation of three separate anaphylatoxins from complement-activated human serum.
    Hugli TE; Gerard C; Kawahara M; Scheetz ME; Barton R; Briggs S; Koppel G; Russell S
    Mol Cell Biochem; 1981 Dec; 41():59-66. PubMed ID: 6977086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of the terminal complement complex in patient plasma following acute myocardial infarction.
    Langlois PF; Gawryl MS
    Atherosclerosis; 1988 Mar; 70(1-2):95-105. PubMed ID: 3258520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis.
    Hopkins P; Belmont HM; Buyon J; Philips M; Weissmann G; Abramson SB
    Arthritis Rheum; 1988 May; 31(5):632-41. PubMed ID: 3259882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement activation produced by biomaterials.
    Chenoweth DE
    Artif Organs; 1988 Dec; 12(6):508-10. PubMed ID: 3265053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Activity of total complement and concentration of its components C1q, C3, C4 and C1-inactivator in cancer].
    Matoses Cuquerella S; O'Connor Miquel C; Lluch Hernández AM; García-Conde Bru J
    Med Clin (Barc); 1988 Dec; 91(20):769-74. PubMed ID: 3266280
    [No Abstract]   [Full Text] [Related]  

  • 17. SC5b-9 is the most sensitive marker in assessing disease activity in Brazilian SLE patients.
    Chiu YY; Nisihara RM; Würzner R; Kirschfink M; de Messias-Reason IJ
    J Investig Allergol Clin Immunol; 1998; 8(4):239-44. PubMed ID: 9777539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement levels of C4, C3C, factor B, and C1 inactivator in peripheral and retroplacental blood of parturient women with EPH gestosis.
    Zdanowicz A; Jabłońska E; Pietruska Z; Bielecki M
    Ann Med Univ Bialyst Pol; 1993; 38(1):60-7. PubMed ID: 7922487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement activation during liver transplantation.
    Tomasdottir H; Henriksson BA; Bengtson JP; Bengtsson A; Stenqvist O; Persson H
    Transplantation; 1993 Apr; 55(4):799-802. PubMed ID: 8475554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered concentrations of terminal complement complexes, anaphylatoxins, and leukotrienes in the coronary sinus during cardiopulmonary bypass.
    Bengtson A; Millocco I; Heideman M; Berggren H
    J Cardiothorac Anesth; 1989 Jun; 3(3):305-10. PubMed ID: 2520655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.